N@N

51.34% Of All NASDAQ Trading Friday Was Short Selling. GBNK, FTBK, CBEY, PTIE, MDSO, NBIX Highest % Of Daily Trading Volume Sh

^{Published on 2009-09-21 07:46:03, Last Modified on 2010-12-22 14:45:41 - WOPRAI}
 

September 21, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, has reviewed the NASDAQ Daily Short Volume Report for Friday, September 18th, 2009 and come to the following statistical conclusions. There were 6,809 stocks with daily short volume reported and total NASDAQ trading volume of 1,887,738,574 shares. Total Daily Short Volume was 969,205,285 shares. 51.34% of all trading on the NASDAQ Friday was short selling. The chart below highlights 6 stocks that had unusually high percentages of their total daily trading volume attributed to short sales. Guaranty Bancorp (NASDAQ: GBNK), Frontier Finanical (NASDAQ: FTBK), Cbeyond (NASDAQ: CBEY), Pain Therapeutics (NASDAQ: PTIE), Medidata Solutions (NASDAQ: MDSO) and Neurocrine Biosciences (NASDAQ: NBIX). To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

DATE SYMBOL SHORT VOLUME TOTAL VOLUME MARKET PERCENT

20090918 GBNK 279,487 301,179 Q 92.80%

20090918 FTBK 114,909 123,856 Q 92.78%

20090918 CBEY 128,005 140,907 Q 90.84%

20090918 PTIE 99,296 109,722 Q 90.50%

20090918 MDSO 91,634 102,752 Q 89.18%

20090918 NBIX 92,655 104,016 Q 89.08%

In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchangesa� naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.

Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.

The SEC refused requests to extend the close-out deadline for fails to deliver to the close of business on the close-out deadline, choosing instead to retain the requirement that all fails be closed out by the beginning of trading on the applicable close-out deadline. The Commission also rejected requests for a fail to deliver exception that would have provided an exception from the close-out requirements if a clearing broker's fail position was below a certain amount but said that it would continue to monitor whether a de minimis or odd lot exception could be warranted.

Guaranty Bancorp (NASDAQ: GBNK) operates as the holding company for Guaranty Bank and Trust Company, which provides various banking products and services to consumers, and small and medium-sized businesses. It primarily engages in generating deposits and originating loans. The companya�s deposit products include demand deposits, negotiable order of withdrawal accounts, money market accounts, individual retirement accounts (IRA), time deposits, and savings accounts. Its lending portfolio comprises commercial and industrial, commercial real estate, construction, residential real estate, small business administration guaranteed, and agriculture loans, as well as home equity lines and miscellaneous consumer loans, including overdraft and lines-of-credit. The company also provides trust services, including personal trust administration, estate settlement, investment management accounts, and self-directed IRAs. As of December 31, 2008, it operated 34 branches in Colorado. The company is based in Denver, Colorado.

Frontier Financial Corporation (NASDAQ: FTBK) operates as the holding company for Frontier Bank that provides various commercial banking services. It primarily engages in generating deposits and originating loans. The companya�s deposit products include demand (checking), NOW, money market, sweep, savings, and certificates of deposit. Its loan portfolio comprises real estate loans, including commercial real estate term loans, construction loans, land development loans, completed lot loans, and residential 1-4 family loans; commercial and industrial loans used to provide working capital or for various purposes, such as to finance the purchase of fixed assets, equipment, or inventory, as well as lines of credit and term loans; and loans for consumer use, such as auto loans, boat loans, home improvement loans, revolving lines of credit, VISA credit cards, and other loans. Frontier Financial Corporation also offers other financial services, including an insurance and investment center that markets annuities, life insurance products, and mutual funds to its customers and the general public; a trust department that offers an array of trust services; and a private banking department to provide personal service to high net worth customers. As of December 31, 2008, it operated 51 offices in western Washington and Oregon. The company was founded in 1978 and is based in Everett, Washington.

Cbeyond, Inc. (NASDAQ: CBEY) provides managed Internet protocol-based communications services to small businesses in the United States. Its services include local and long distance voice services, broadband Internet access, mobile voice and data, email, voicemail, Web hosting, secure backup and file sharing, fax-to-email, virtual private network, and other communications and information technology(IT) services. The company also offers mobile voice and data services in conjunction with its landline-based services via its mobile virtual network operator relationship with a nationwide wireless network provider. It offers its services through direct sales force, as well as through channel partners, including value-added resellers, local area network consultants, and other IT and telecommunications consultants. The company was formerly known as Cbeyond Communications, Inc. and changed its name to Cbeyond, Inc. in July 2006. Cbeyond was founded in 2000 and is headquartered in Atlanta, Georgia.

Pain Therapeutics, Inc. (NASDAQ: PTIE), a biopharmaceutical company, engages in the research and development of novel drugs. It has four drug candidates in clinical development programs, which include Remoxy, a novel controlled-release oral capsule form of oxycodone; PTI-202 and PTI-721, which are abuse-resistant forms of opioid drugs; and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. The company is also developing a technology for the treatment of hemophilia in patients. Pain Therapeutics, Inc. has a strategic alliance with King Pharmaceuticals, Inc. for the development and commercialization of Remoxy, PTI-202, PTI-721, and another abuse-resistant opioid painkiller. The company was founded in 1998 and is based in San Mateo, California.

Medidata Solutions, Inc. (NASDAQ: MDSO) provides hosted clinical development solutions for life science organizations worldwide. Its solutions include software and services that allow customers to achieve clinical results by streamlining the design, planning, and management of key aspects of the clinical development process, including protocol development, contract research organizations (CRO) negotiation, investigator contracting, the capture and management of clinical trial data, and the analysis and reporting of that data on a worldwide basis. The company primarily offers Medidata Rave, a comprehensive platform that integrates electronic data capture with a clinical data management system in a single solution. It also provides Medidata Designer application, a clinical trial protocol authoring tool that enables customers to write trial protocols and automatically configure Medidata Rave. In addition, Medidata Solutions offers Medidata Grants Manager, which enables its customers to benchmark their investigator budgets against industry data, as well as their own grant history; and Medidata CRO Contractor that focuses on benchmarks for CRO outsourcing, budgeting, and negotiation. Further, the company provides professional services, including implementation services to meet customersa� data requirements for various indications; workflow design to meet the needs of different study phases and global regulatory requirements; and guidance on best practices for using its application services. Its customers include pharmaceutical, biotechnology, and medical device companies; academic institutions; clinical research organizations; and other entities engaged in clinical trials. The company markets and sells its application services through a direct sales force and through relationships with CROs and other strategic partners. Medidata Solutions, Inc. was founded in 1999 and is headquartered in New York, New York.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The companya�s research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan. Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies or third parties pay $995 per month to purchase data for information provided in monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net